Default company panoramic image

Azee Pharmaceuticals

We plan to rapidly develop and license a new break-through drug for treating chronic pain and, in 3 years, provide a high ROI for investors.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Dublin, CA, USA
  • Currency USD
  • Founded September 2003
  • Employees 1
  • Website

Company Summary

Azee Pharmaceuticals is an early-stage, drug-development company that is developing a new analgesic drug for treatment of chronic pain to address the growing need for more effective therapies. Azee is developing a break-through drug that can acquire significant market share. The business plan focuses on rapidly establishing clinical proof-of-concept, and then in 3 years licensing the drug and giving investors a possible early exit and high ROI.


  • Default avatar
    Richard Tanaka

    Dr. Tanaka has over 25 years of pharmaceutical experience in both large (Bristol-Myers Squibb) and small companies (Axys Pharmaceuticals, Genesoft Pharmaceuticals). He has worked in multiple therapeutic areas (cardiovascular, inflammation, cancer, infectious disease, chronic pain), and he was also the principal investigator and project leader for a DARPA contract that received $21 million in government funding.

  • Default avatar
    Heinz Gschwend
    Director, Board of Directors

    Dr. Gschwend has over 35 years of pharmaceutical experience (former head of central research, Ciba Geigy). Dr. Gschwend also served on the scientific advisory board for several biotech companies.

  • Default avatar
    James Hudak
    Director, Board of Directors

    Mr. Hudak has over 20 years of healthcare experience (former CEO of United Behavioral Health). He is currently the CEO of Paradigm Management Services (Walnut Creek, CA).


  • Default avatar
    Squire, Sanders, and Dempsey
    Default avatar
    Waterman, Fallahee, Hanson, and Associates

Previous Investors

  • Default avatar
    Mr. James Hudak